Embecta Corp · Q4 2024 earnings

Briefing

Reported strong fourth quarter and end to fiscal year, exceeding expectations across key financial metrics and executing strategic priorities.

Embecta Corp. reported a strong fourth quarter with revenues up 1.5% to $286.1 million. The company is discontinuing its insulin patch pump program and initiating an organizational restructuring plan to streamline operations and reduce costs. They anticipate pre-tax charges of $35 million to $45 million in fiscal year 2025 related to the restructuring plan and expect annualized pre-tax cost savings of $60 million to $65 million.

• Reported Revenues of $286.1 million, up 1.5%.
• Adjusted Revenues of $290.2 million, up 4.1% on an adjusted constant currency basis.
• Net income of $14.6 million and earnings per diluted share of $0.25.
• Announced a dividend of $0.15 per share.

Headline financials

Revenue & EPS history

For fiscal year 2025, excluding the patch pump program, the Company expects Reported Revenues between $1,093 million and $1,110 million, Adjusted Gross Margin between 63.25% and 64.25%, Adjusted Operating Margin between 29.00% and 30.00%, Adjusted Earnings per Diluted Share between $2.70 and $2.90, and Adjusted EBITDA Margin between 35.50% and 36.50%.